Market News AIOpen the app

KYNB stock news · Kyntra Bio, Inc.

Stories about Kyntra Bio, Inc. (KYNB) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for KYNB

Follow Kyntra Bio, Inc. (KYNB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KYNB
Free on the App Store and Google Play, or on the web.
  1. Nov 16, 2026, 4:17 PM ET · Market

    Kyntra Bio, Inc. shared its Q3 2026 results, showing a profit of $0.2 million and plans for a new drug trial.

    Neutral

    Kyntra Bio cut its payment cap by $60 million and ended 2 programs after weak results. Savings and a failed trial, plus funding needed for Phase 3, leave a mixed picture.

  2. Oct 6, 2026, 6:02 PM ET · Market

    Kyntra Bio, Inc. has been told it might be removed from Nasdaq for not following the rules.

    Bad for KYNB

    Kyntra Bio has not met Nasdaq's continued-listing rules, and staff plans to delist its stock. A hearing keeps it listed for now, but the risk remains serious.

  3. Oct 1, 2026, 7:33 AM ET · Market

    Kyntra Bio, Inc. says some directors and officers are leaving, while new ones are being chosen.

    Neutral

    Kyntra Bio added a director with biopharma deal experience as a longtime director left. The changes appear balanced and do not clearly shift the company's prospects.